Relmada Therapeutics (RLMD) Fundamental Analysis: Revenue, Earnings & Valuation

4.61 / 10

Netural

Fundamental metrics average 4.6/10. Strengths include strong accounts‑receivable turnover and interest coverage. Weak points are low fixed‑asset turnover and high income‑tax‑to‑profit ratio. Overall, the fundamentals are average, warranting a guarded appraisal.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score3/3

Weight42.27%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight2.25%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-2.40%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-2.38%

1M Return-0.65%

PB-ROE

Value3.40

Score1/3

Weight22.41%

1M Return5.22%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-5.40%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-4.45%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.68%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-2.63%

1M Return-0.74%

Asset-MV

Value-0.48

Score2/3

Weight53.02%

1M Return9.91%

Is RLMD fundamentally strong?

RLMD scores 4.61/10 on fundamentals and holds a Fair valuation at present. Backed by its -94.05% ROE, 0.00% net margin, -11.94 P/E ratio, 7.92 P/B ratio, and 45.28% earnings growth, these metrics solidify its Netural investment rating.